Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice.

The publication “Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice.” is organized in H2HUBB under the research focus hydrogen water cancer supportive care study 2009. The publication is cited as Nakashima-Kamimura N, Mori T, Ohsawa I, Asoh S, Ohta S, Cancer chemotherapy and pharmacology, 2009. This uncontrolled human study examined Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice. The abstract describes Human participants; hydrogen delivered as hydrogen water. The abstract reports: Hydrogen has potential for improving the quality of life of patients during chemotherapy by efficiently mitigating the side effects of cisplatin. This is an automated editorial draft based on the abstract and requires source review before publication.

Hydrogen water cancer supportive care study 2009 overview

Cisplatin is a widely used anti-cancer drug in the treatment of a wide range of tumors; however, its application is limited by nephrotoxicity, which… Animal research can identify biological effects and support future investigation, but it cannot by itself establish safety or effectiveness in humans.

Study design and hydrogen intervention

Publication type: Animal study. Evidence type: Preclinical animal evidence. Research model or population: Mouse model. Blinding: Unknown. Control status: Unknown.

Delivery method: Hydrogen water. Hydrogen concentration: 0.8 mM.

Reported findings and scientific interpretation

For this hydrogen water cancer supportive care study 2009, the study record reports the following: The abstract reports: Hydrogen has potential for improving the quality of life of patients during chemotherapy by efficiently mitigating the side effects of cisplatin.

These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.

How this research record was prepared

H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.

Limitations, safety, and original source

Limitations: Cisplatin is a widely used anti-cancer drug in the treatment of a wide range of tumors; however, its application is limited by nephrotoxicity, which…

Safety: Despite its protective effects against cisplatin-induced toxicity, hydrogen did not impair anti-tumor activity of cisplatin against cancer cell lines in vitro and tumor-bearing mice…

This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.